Effective concentration-based serum pharmacodynamics for antifungal azoles in a murine model of disseminated Candida albicans infection
暂无分享,去创建一个
[1] D. S. Hage,et al. Characterization of drug interactions with serum proteins by using high-performance affinity chromatography. , 2011, Current drug metabolism.
[2] Jeong-Yoon Kim,et al. Role of the RAM network in cell polarity and hyphal morphogenesis in Candida albicans. , 2008, Molecular biology of the cell.
[3] C. Lass‐Flörl,et al. Activities of Antifungal Agents against Yeasts and Filamentous Fungi: Assessment according to the Methodology of the European Committee on Antimicrobial Susceptibility Testing , 2008, Antimicrobial Agents and Chemotherapy.
[4] A. Yamada,et al. Use of a serum‐based antifungal susceptibility assay to predict the in vivo efficacy of novel echinocandin compounds , 2008, Microbiology and immunology.
[5] F. Ikeda,et al. Direct Comparison of the Pharmacodynamics of Four Antifungal Drugs in a Mouse Model of Disseminated Candidiasis Using Microbiological Assays of Serum Drug Concentrations , 2007, Microbiology and immunology.
[6] K. Garey,et al. Association of Fluconazole Area under the Concentration-Time Curve/MIC and Dose/MIC Ratios with Mortality in Nonneutropenic Patients with Candidemia , 2006, Antimicrobial Agents and Chemotherapy.
[7] J. Lopez-Ribot,et al. Inhibition of Filamentation Can Be Used To Treat Disseminated Candidiasis , 2006, Antimicrobial Agents and Chemotherapy.
[8] A. Yamada,et al. Determination of Antifungal Activities in Serum Samples from Mice Treated with Different Antifungal Drugs Allows Detection of an Active Metabolite of Itraconazole , 2006, Microbiology and immunology.
[9] D. Snydman,et al. Fluconazole MIC and the Fluconazole Dose/MIC Ratio Correlate with Therapeutic Response among Patients with Candidemia , 2005, Antimicrobial Agents and Chemotherapy.
[10] D. Loebenberg,et al. Pharmacodynamics of a New Triazole, Posaconazole, in a Murine Model of Disseminated Candidiasis , 2004, Antimicrobial Agents and Chemotherapy.
[11] J. Lopez-Ribot,et al. Engineered Control of Cell Morphology In Vivo Reveals Distinct Roles for Yeast and Filamentous Forms of Candida albicans during Infection , 2003, Eukaryotic Cell.
[12] D. Andes,et al. In Vivo Pharmacokinetics and Pharmacodynamics of a New Triazole, Voriconazole, in a Murine Candidiasis Model , 2003, Antimicrobial Agents and Chemotherapy.
[13] D. Andes. In Vivo Pharmacodynamics of Antifungal Drugs in Treatment of Candidiasis , 2003, Antimicrobial Agents and Chemotherapy.
[14] D. Andes,et al. In Vivo Pharmacodynamics of a New Triazole, Ravuconazole, in a Murine Candidiasis Model , 2003, Antimicrobial Agents and Chemotherapy.
[15] J. Karlowsky,et al. Influence of Human Serum on Antifungal Pharmacodynamics with Candida albicans , 2001, Antimicrobial Agents and Chemotherapy.
[16] L. See,et al. Clinical Correlates of Antifungal Macrodilution Susceptibility Test Results for Non-AIDS Patients with Severe CandidaInfections Treated with Fluconazole , 2000, Antimicrobial Agents and Chemotherapy.
[17] M. Klepser,et al. Postantifungal Effects of Echinocandin, Azole, and Polyene Antifungal Agents against Candida albicans andCryptococcus neoformans , 2000, Antimicrobial Agents and Chemotherapy.
[18] D. Andes,et al. Characterization and Quantitation of the Pharmacodynamics of Fluconazole in a Neutropenic Murine Disseminated Candidiasis Infection Model , 1999, Antimicrobial Agents and Chemotherapy.
[19] Michael H. Miller,et al. Pharmacodynamics of Fluconazole in a Murine Model of Systemic Candidiasis , 1998, Antimicrobial Agents and Chemotherapy.
[20] Ronald N. Jones,et al. Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans , 1997, Antimicrobial agents and chemotherapy.
[21] J. Prieto,et al. Activity of fluconazole: postantifungal effect, effects of low concentrations and of pretreatment on the susceptibility of Candida albicans to leucocytes. , 1994, The Journal of antimicrobial chemotherapy.
[22] M. Saag,et al. Azole antifungal agents: emphasis on new triazoles , 1988, Antimicrobial Agents and Chemotherapy.
[23] H. Derendorf,et al. Pharmacokinetic/Pharmacodynamic Profile of Posaconazole , 2010, Clinical pharmacokinetics.
[24] Clinical,et al. Reference method for broth dilution antifungal susceptibility testing of yeasts : Approved standard , 2008 .
[25] H. Derendorf,et al. Pharmacokinetic/Pharmacodynamic Profile of Voriconazole , 2006, Clinical pharmacokinetics.
[26] F. del Moral,et al. Activity of voriconazole: post-antifungal effect, effects of low concentrations and of pretreatment on the susceptibility of Candida albicans to leucocytes. , 1999, Scandinavian journal of infectious diseases.